Evidence map›Paper›PMID 33198208›Full record

ArticleMolecules (Basel, Switzerland)2020

Cancer Research in the "Chemical Biology" Section of the Journal

Timothy W Corson

Abstract readEditorial
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Timothy W CorsonDepartments of Ophthalmology, Biochemistry and Molecular Biology, and Pharmacology and Toxicology, and the Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-1402-7875

Funding

Ferrochelatase as a mediator of ocular angiogenesisR01EY025641 · NEI · UNIVERSITY OF TORONTO · PI Timothy W Corson · 2016 to 2026
$3.5M
Targeting the Ref-1 signaling node for treating ocular neovascularizationR01EY031939 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI CORSON, TIMOTHY W, KELLEY, MARK R. · 2020 to 2023
$1.7M
BrightFocus Foundation M2019069NIH HHS R01EY025641NIH HHS R01EY031939
6 · The paper itself

Abstract

The Chemical Biology Section of

Indexed as

AnimalsAntineoplastic AgentsBiomedical ResearchChemistry, PharmaceuticalComputational BiologyHumansNeoplasmsPeptidesPeriodicals as TopicAntineoplastic AgentsPeptides

Identifiers

PMID33198208
PMCPMC7697467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.